#### (On the Letterhead of Statutory Auditors/ Independent Auditors)

Certificate of Net-Worth in connection with application of M/s for
ncentive under <b>Production Linked Incentive Scheme (PLI)</b> for promotion of domestic
manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active
Pharmaceutical Ingredients (APIs) In India, as notified vide notification No. 31026/16/2020
dated July 21, 2020.
This is to certify that the Net worth of M/s (Name of the applicant) for the
ourpose of the Scheme, as on is Rupees as per the statement
of computation given hereunder:

### **Net-worth of Applicant – (mention Name)**

Particulars	Amount
Paid-up Share Capital	
Free Reserves including Share Premium	
Reserve but Excluding Revaluation Reserve	
Investment Fluctuation Reserve, if any	
Credit Balance in P&L	
Total (A)	
Debit balance in P&L	
Accumulated Losses	
Intangible Assets	
Total (B)	
Net Worth (A-B)	

It is certified that the computation of Net worth, based on our scrutiny of the books of accounts, records and documents, is true and correct.

# Net-worth of Group Company – (mention Name and relationship as to basis of considering as Group Company)

To be signed by Statutory Auditors/ Independent Auditors with particulars required for attestation as per ICAI Guidelines and Unique Document Identification No. (UDIN)

#### Note:

- The certificate should be signed by the Statutory Auditors of Company

- The net-worth should be given as on the date of application. There may be some estimation involved for certain items e.g. balance of P&L account. In this case, provide the balance as per last audited balance sheet and estimation amount e.g. balance as on March 31, 2020 Rs. 100, estimated for the period from April 01 to ......... Rs. 5. Considered for net-worth – Rs. 105.

Annexure 6

#### Consent for audit of their manufacturing site/offices

(To be signed by full time Director / CEO / MD of the company /Partners of the firm/Proprietor (as the case may be) duly depicting the Name & designation and submitted on official stationery of the applicant along- with the authorization to do so)

- 1. Whereas, the applicant namely (name of manufacturer with address) has submitted an application under Production Linked Incentive Scheme (PLI) for domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/Active Pharmaceutical Ingredients (APIs) to Department of Pharmaceuticals (DoP), Government of India seeking incentives for the application pertaining to manufacturing.......(Eligible Product) at......(location(s)).
- 2. Now, therefore, the applicant or its agencies or its consultants engaged with the process of manufacturing of eligible products shall allow the PMA or any other authority as designated by DoP for verification of facility and documents submitted for the approval of application and disbursement of incentives under PLI Scheme.

Date

(Name & designation with address)

Full time Director / CEO / MD of the company/ Partner/ Proprietor of the firm

#### Proforma for Integrity compliance-Initial Undertaking

(To be signed by full time Director / CEO / MD of the company /Partners of the firm/Proprietor (as the case may be) duly depicting the Name & designation and submitted on official stationery of the applicant along- with the authorization to do so)

#### **FORMAT A**

- 2. Now, therefore, the applicant including its officers / representatives commits and undertakes that he / she will take all measures necessary to prevent corruption. He / She commits to observe the following principles during his / her association / engagement with DoP or its agencies or its consultants engaged with the process of appraisal and verification of application for the approval of application and disbursement of incentives under PLI Scheme.
  - **2.1.** The PLI applicant will not directly or through any other person or firm, offer, promise or give to any of the DoP's officer(s) or consultant or agency representative (appraisal or/and PMA appointed by DoP to handle the application) involved in the process of dealing with application or to any third person any material or other benefit which he/she is not legally entitled to in order to obtain in exchange any advantage of any kind whatsoever before or during or after the process of the application for grant of approval or disbursement of incentives under PLI.
  - **2.2.** The PLI applicant will not commit any offence under the relevant Indian Penal Code, 1860/Prevention of Corruption Act, 1988. Further, the applicant will not use improperly, for purposes of competition or personal gain, or pass on to others, any information or document provided by the DoP.
  - **2.3.** The PLI applicant shall disclose the name and address of the duly authorized Agents/Representatives who will be dealing with DoP or its agencies and the remuneration of

these agents or representatives shall not include any hidden amount or component to get the work done in undue manner or causing inducement of whatsoever nature whether in cash or kind to influence the normal process or practice of work.

- **2.4.** The PLI applicant will disclose any and all payments he/she has made, is committed to or intends to make to agents, brokers or any other intermediaries, other than regular employees or officials of the applicant, in connection with the grant of approval or/and disbursement of incentives.
- **2.5.** The applicant will not offer any illicit gratification to obtain unfair advantage.
- **2.6.** The applicant will not collude with other parties to impair transparency and fairness.
- **2.7.** The applicant will not give any advantage to anyone in exchange for unprofessional behaviour.
- **3.** The applicant declares that no pervious transgressions occurred in the last 3 years with any other Company in any country conforming to the anti-corruption approach or with any other Public Sector Enterprises/Central or State Government or its any instrumentality in India.
- 4. The applicant agrees that if it is found that the applicant has made any incorrect statement on this subject, the application will be closed or rejected and DoP reserve the right to initiate legal action of whatsoever nature. In case if DoP has disbursed the incentives under PLI, the amount disbursed to applicant be recoverable along with interest calculated at 3 years SBI MCLR prevailing on the date of disbursement, compounded annually, besides blacklisting of the applicant and initiation of legal action of whatsoever nature at the discretion of DoP.
- **5.** The contents of the above undertaking have been gone through and after understanding the same is being executed / given on.......day of ...... (month / year)

Date Signature

(Name & designation with address)

Full time Director / CEO / MD of the company/ Partner/ Proprietor of the firm

#### (On the Letterhead of Applicant)

(To be signed by full time Director / CEO / MD of the company /Partners of the firm/Proprietor (as the case may be) duly depicting the Name & designation and submitted on official stationery of the applicant along- with the authorization to do so)

In connection with our application for incentive under **Production Linked Incentive Scheme (PLI)** for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India as notified vide notification No. 31026/16/2020 dated July 21, 2020.

The details of any Legal Case pending against applicant or its promoters are given as under:

Sr. No.	Forum where pending	Relevant Act	Financial Impact, if any	Brief nature of Dispute and current status

This is to confirm that there is no legal case pending against by the applicant or its promoters, except as given above:

Date (Name & designation with address)

Full time Director / CEO / MD of the company/ Partner/ Proprietor of the firm

## (On the letterhead of the applicant)

Subj	<b>ject:</b> Authorisation to act as Authorised Signatory on behalf of M/s (name of the applicant) for submission of application, information and all correspondence with Project Management Agency in connection with PLI Scheme
(PLI) Inter	onnection with our application for incentive under Production Linked Incentive Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug mediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India as notified vide ication No. 31026/16/2020 dated July 21, 2020.
The incor creat not a Partrits Re	Companies Act, 2013 (erstwhile Act of 1956)/ a Limited Liability Partnership Firm roorated and registered under The Limited Liability Partnership, 2008/ a Partnership Firm ted under The Partnership Act, 1932/ a Sole Proprietorship Firm [strike out whichever is applicable] with Corporate Identity Number/ Limited Liability nership Identification Number [applicable in case of Company or Limited Liability nership] and Permanent Account Number (PAN No.) and having registered Office at, do hereby authorise Mr
•	Submitting the application on behalf of M/s (name of the applicant) and all related data, documents, certificates and information
•	To make representation, give undertakings and correspond with IFCI being the Project Management Agency
•	To submit correct and complete data, document, certificates and information in connection with determination of baseline sales and investments, claim verification and any other aspect related to PLI scheme
We d	do hereby undertake and affirm that :-
•	Mr (name and designation of the authorised signatory) is competent and authorised to submit complete and correct data, documents, certificates and information related to all aspects of PLI scheme and

- Any data, documents, certificate and information submitted by ....... (name and designation of authorised signatory), their statement and explanations shall be binding on M/s ...... (name of the applicant).
- He is also authorised individually to accept, issue and make all communication in relation to the proceedings stated therein.

The sample signature of Mr..... (Name & Designation of authorised signatory) is endorsed herewith for reference:

Signature of the Authorised Signatory	Signature of Person Authorising
Signature or the Mathonised Signatory	orginatare or recommending
Namos	Namai
Name:	Name:
Designation	Designation
Designation	Designation

To be signed by Managing Director or Equivalent of the Company/ Designated Partner of Limited Liability Partnership Firm/ Managing Partner or any Active Partner, where there is no managing partner, in case of Partnership Firm/ Proprietor of the Proprietor Firm

In case authorisation is through Board of Directors, please attach certified copy of Board Resolution (Copy of Board Resolution to be authenticated by the Company Secretary/ Managing Director of the Company)

# Undertaking as required clause 2.4 of the application form annexed with **Guidelines for the Operation of Production Linked Incentive Scheme (PLI)**

In connection with our application for incentive under <b>Production Linked Incentive</b>
Scheme (PLI) for promotion of domestic manufacturing of critical Key Starting Materials
(KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India as
notified vide notification No. 31026/16/2020 dated July 21, 2020.

We, (name of the applicant) a	Company incorporated and registered under
the Companies Act, 2013 (erstwhile Act of 1	1956)/ a Limited Liability Partnership Firm
incorporated and registered under The Limited Li	iability Partnership, 2008/ a Partnership Firm
created as per The Partnership Act, 1932 / a Sole	e Proprietorship Firm [strike out whichever is
not applicable] with Corporate Identity Number	er/ Limited Liability
Partnership Identification Number [applicable	in case of Company or Limited Liability
Partnership] and Permanent Account Number (Pa	PAN) and having its
Registered Office at	do hereby undertake as under:

- 1. That the names of the applicant or its directors/ partners/ proprietor do not figure in any list of defaulters/willful defaulters/Fraud circulated by RBI or CIBIL or SEBI or any Bank or Financial Institution in India.
- 2. That none of our associate or group concerns in India have been classified as defaulter/ willful defaulters by any Banks or Financial Institution.
  - (In case of LLP, Partnership Firm and Proprietorship Firm any business enterprise in India, wherein any partner of LLP/ Partnership Firm, proprietor of Proprietor Firm are having beneficial interest/ ownership shall also be considered as Group Concern)
- That the names of the applicant, its directors/ partners/ proprietor or any associate/ group concern in India do not figure in any debarred list circulated by RBI or CIBIL or SEBI.
  - (In case of LLP, Partnership Firm and Proprietorship Firm any business enterprise in India, wherein any partner of LLP/ Partnership Firm, proprietor of Proprietor Firm are having beneficial interest/ ownership shall also be considered as Group Concern)

4. That the applicant, its directors/ partners/ proprietor or any associate/ group concern in India has not been declared as insolvent/ bankrupt and there is no proceeding pending/ underway in connection with insolvency or bankruptcy of applicant or aforementioned persons.

5. That there is no litigation/ dispute/ proceedings pending against the applicant or any of its director/ partner/ proprietor or any group concern in India, in connection with any of the above mentioned clauses from 1 to 4.

6. That we will shall immediately inform Project Management Agency (PMA) and Department of Pharmaceutical (DoP) in case of name of applicant, its directors/ partner/ proprietor or any associate/ group concern in India is declared in any of the list mentioned above or any proceedings in relation to the above is initiated by RBI or CIBIL or SEBI or any Bank or Financial Institution or any other stakeholder.

Please give complete details and present status, if response to any declaration mentioned at 1 to 6 above in not Nil.

### **Authorised Signatory**

Name

Designation

Date

To be signed by - (i) Company Secretary of the Company (not the practicing company secretary) or in case applicant is not having a Company Secretary, by the Managing Director of the Company.

(ii) In case of LLP, Partnership Firm and Proprietorship Firm – to be signed by Designated Partner of LLP/ Manging Partner or any Active Partner, where there is no Manging Partner, in case of Partnership Firm/ Proprietor of Proprietor Firm.

In case authorisation is through Board of Directors, please attach certified copy of Board Resolution (Copy of Board Resolution to be authenticated by the Company Secretary/ Managing Director of the Company)

#### Name of the Applicant

#### **Ownership/ Shareholdin Pattern**

**Ref:** our application for incentive under Production Linked Incentive Scheme (PLI) for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India as notified vide notification No. 31026/16/2020 dated July 21, 2020.

S. No.	Shareholder	Address	No. of Shares	Share Capital	% Shareholding

#### To be signed by

To be signed by - Company Secretary of the Company (not the practicing company secretary) or in case applicant is not having Company Secretary, by the Managing Director of the Company (In case authorisation is through Board of Directors, please attach certified copy of Board Resolution (Copy of Board Resolution to be authenticated by the Company Secretary/ Managing Director of the Company)

In case of LLP, Partnership Firm and Proprietorship Firm – to be signed by Designated Partner of LLP/ Manging Partner or any Active Partner, where there is no Manging Partner, in case of Partnership Firm/ Proprietor of Proprietor Firm.